Jiangxi Serum Pharma Industries Co., Ltd. is a premier professional supplier of pharmaceutical and nutritional products in China. With nearly 10 years of expertise, we specialize in high-efficacy medications including Amoxicillin and Potassium Clavulanate formulations.
Amoxicillin and Potassium Clavulanate (commonly referred to as Co-amoxiclav) represents a breakthrough in antibiotic therapy. By combining a broad-spectrum penicillin with a beta-lactamase inhibitor, this medication restores the efficacy of amoxicillin against resistant bacterial strains.
Pathogenic bacteria often develop resistance by producing enzymes called beta-lactamases. Potassium Clavulanate acts as a "suicide inhibitor," binding to these enzymes and preventing them from destroying the Amoxicillin molecule. This allows the amoxicillin to reach its target: the bacterial cell wall synthesis process.
Highly effective for Sinusitis, Bronchitis, and Community-acquired Pneumonia (CAP) caused by H. influenzae or Moraxella catarrhalis.
The gold standard for treating animal bites, cellulitis, and severe dental abscesses involving beta-lactamase producing Staphylococci.
Prescribed for complicated UTIs where resistance to standard amoxicillin is prevalent among E. coli strains.
In the current global pharmaceutical landscape, China stands as the primary hub for Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Sourcing from Jiangxi Serum Pharma provides distinct strategic advantages:
Leveraging China's industrial clusters, we offer competitive pricing for bulk Amoxicillin and Potassium Clavulanate tablets without compromising on GMP standards.
Our partners utilize cutting-edge bio-fermentation and co-crystallization technologies to ensure the stability of Clavulanate, which is highly sensitive to moisture.
We provide full documentation support, including COA, GMP certificates, and stability data to satisfy the regulatory requirements of various health ministries.
We understand that every market has unique regulatory hurdles. Whether it's the BP (British Pharmacopoeia), USP (United States Pharmacopeia), or local regional standards in Southeast Asia and Africa, our team ensures that the products are registered and compliant for immediate distribution.
The pharmaceutical world is shifting toward "Precision Medicine" and "Smart Manufacturing." Serum Pharma is at the forefront of these trends:
Note on Breakthroughs: Similar to the rapid 50-day FDA approval of Eli Lilly’s oral small-molecule GLP1 (Foundayo™), the antibiotic sector is seeing accelerated pathways for formulations that address multi-drug resistant (MDR) infections.
